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ABSTRACT
Epigenetics is defined as the study of heritable changes of DNA. One suc h
component of epigenetic regulation is DNA methylation in humans. In neoplastic cells
epigenetic controls are often dysregulated, especially in the promoter region of CpG
islands. Global hypomethylation along with region specific hypermethylation of CpG
islands in the promoter region of tumor suppressor is often indicative of neoplastic cells.
In cancer, CpG island cytosine hypermethylation has been observed in more than fifty
genes, including known tumor suppressor and DNA repair genes.
Squamous cell carcinoma (SCC), lichen sclerosis (LS), and adjacent normal
tissues were obtained by radical vulvectomies of over one hundred patients. Normal
unassociated tissues were also collected in the same manner. The disease process of LS
provides an environment conducive to oxidative damage and increases in free radicals.
Increased methylation in the promoter regions of specific tumor suppressor and DNA
repair genes were anticipated to display a progression to malignancy from normal tissue
to LS to SCC.
Hypermethylation patterns of p16, p15, O6 methyl guanine methyl transferase
(MGMT), glutathione S-transferase pi (GSTP1) were examined by methylation specific
polymerase chain reaction (MSP) to obtain an etiological model of vulvar cancer. SCC
samples exhibited 26% and 34% methylation in p16 and p15 genes. LS samples
displayed 22% and 31% methylation in p16 and p15. The level of hypermethylation in
SCC and LS associated samples was significantly different from normal samples in both
p16 and p15 genes, suggesting that silencing of these two genes is an early and important

vii

event in vulvar squamous cell carcinoma. GSTP1 and MGMT were not found to have a
statistically significant difference in any of the tissues tested.
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CHAPTER 1
INTRODUCTION AND LITERATURE REVIEW

1.1

Introduction
The modern world has brought about much advancement in the sciences. These

advances have brought about many chemicals that are used in processing and
development of many of the products that we consume regularly. Due to the advent of
modern technology, new chemicals enter the environment daily. Governmental
regulatory agencies have done much to combat the release of dangerous chemicals, but
still many of these are often released into the environment at extremely low levels that
are difficult to monitor and detect. It has been estimated that the number of organic
chemicals that are continually being brought into the environment may include more that
100,000 chemicals (Pitot and Dragan 2001). One can be exposed to chemicals by many
routes. Contamination of waste, water, food supplies, and air are common routes by
which one might be exposed. In fact, chemical exposure occurs in every nation to every
person on a daily basis though multiple pathways. Developing countries that do not have
stringent environmental regulations are most concerning. These countries, along with
large consumers such as the United States, release contaminants that can often travel
globally affecting those in other regions of the world.
Many of the properties, routes of exposure, and toxicological effects of toxic
chemicals are known. Modern science has given us the ability to classify thousands of
chemicals and determine the detrimental effects of exposure. Xenobiotics are substances,
natural and manmade, that are foreign to a biological system (Eaton and Klaassen 2001).
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The science of toxicology focuses on the adverse effects of xenobiotics on living
organisms. Although science, in particular toxicology, has given us a greater
understanding of exposures and chemicals, much is still not understood. Modern
toxicology could not possibly determine all deleterious effects of chemicals on animals,
humans, or the environment. Furthermore, regulation regarding the release of kno wn
hazardous chemicals cannot control all possible exposures.
Exogenous agents, including cigarette smoke, dietary factors, occupational and
environmental chemical exposures, and biologic agents, are causative factors in many
cancers (Moore, Huang et al. 2003). Direct associations between exogenous agents and
cancer were first made over 200 years ago The first report of carcinogenesis associated
with chemicals is attributed to the English physician Percivall Pott (Pitot and Dragan
2001). Pott described a correlation between scrotum cancer and chimney sweeps, which
was caused by soot exposure over the course of their lifetime. Pott was in essence the
forefather of the branch of toxicology which we refer to as chemical carcinogenesis.
Chemical carcinogenesis is the study of exogenous chemicals and their ability to induce
cancer.
1.2

Genetics vs. Epigentics
The genome is controlled by many processes which regulate gene expression. It

is now evident that two forms of information are encoded in the genome; genetic and
epigenetic. Genetic information, which is organized using nucleotide bases, provides the
essential instructions for manufacturing proteins. Epigenetic information provides
additional instructions that facilitate how genetic information will be utilized. Epigenetic
changes are those that are defined as heritable changes of DNA, not involving changes in
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DNA sequence, that regulate gene expression (Dunn, Verma et al. 2003). The far more
recent study of epigenetics is beginning to answer many questions about gene regulation
that genetics could not explain. DNA methylation and histone modification are the major
epigenetic mechanisms that can affect gene expression in mammals(Wolffe and Matzke
1999).
1.3

DNA Damage
DNA damage can be induced by one of two phenomenons: damage from

endogenous agents and mistakes occurring in cell replication and repair. Agents that
damage DNA include ionizing radiation, ultraviolet light, chemicals, and others such as
hydrocarbons. These chemicals react with DNA and may cause damage such as adduct
formation, oxidative alteration, and strand breakage (Gregus and Klaasen 2001).
Damage to DNA usually involves the alteration of genes in somatic cells.
Somatic cell mutations affect a given cell and every cell in its line after division, as
opposed to germ cells which affect every cell in an individual’s offspring. Somatic cell
mutations occur during chromosomal replication when cells are dividing. During normal
chromosomal replication, nucleotides are copied within cells with great precision. In the
course of copying a few billion nucleotides, fewer than one hundred errors are likely to
be made, most of them inconsequential (Varmus and Weinberg 1993). Table 1.1 lists
some of the genetic variations that might occur in the genetic sequence if replicatio n is
not faultless.
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Table 1.1 DNA mutations
Mutation
Classification
Genetic

Mutation Type
Single Base Substitution (Missense)

Effects
Amino acid substitution, new
gene product with altered
activity
Single Base Substitution (Nonsense) Premature translational
termination, truncated protein,
altered regulation of normal
gene product
Frame Shift
Shift in reading frame, Multiple
amino acid substitutions,
Premature translational
termination
Insertion
Addition of multiple amino
acids, Transcriptional and/or
translational termination
Inversion
Amino acid substitution
Deletion

Loss of amino acids, Shift of
reading frame

Double Strand Breaks

Premature translational
termination

Single Strand Breaks

Premature translational
termination

Translocation

Aneup loidy

Addition of multiple amino
acids, Loss of amino acids,
Transcriptional and/or
translational termination or up
regulation, chimeric gene
products
Addition of multiple amino
acids, Transcriptional and/or
translational up regulation
Loss or Gain of Chromosomes

Adduct

Secondary Alterations

Methylation

Up-regulation or downregulation of gene expression

Acetylation

Up-regulation or downregulation of gene expression

Amplification

Epigenetic

4

If a mistake has occurred during replicatio n, the cell copes with the DNA damage
in one of three ways. In the case of extensive damage the cell will undergo a death
pathway. If the damage is extensive necrosis will occur. Necrosis is a pathological
process in which cells lose membrane integrity and die. The loss of integrity often
induces an inflammatory response. Apoptosis is a programmed cell death that results
from an energy dependent, endogenous cellular process. Membrane integrity is
preserved and inflammatory reactions are minimized. In the event that the damage is less
severe, the cell enters one of its many repair processes that are part of a generalized
cellular DNA damage response network (Preston and Hoffmann 2001).
1.4

DNA Repair
Three general categories of recovery phenomena are direct reversal, excision

repair, and tolerence (Cleaver 1984). All three deal with damaged DNA bases and DNA
strand breaks.
Direct chemical reversal is a mechanism that is very common in the repair of
damaged bases. It often involves enzymes such as DNA photolyase which cleave
adjacent pyrimidines dimerized by UV light (Gregus and Klaasen 2001). Minor adducts,
including methyl groups, are often removed by DNA repair proteins encoded by the
methyl guanine methyl transferase (MGMT) gene (Pitot and Dragan 2001).
Excision Repair includes two forms of repair: base excision repair and nucleotide
excision repair. Base excision repair, like direct chemical reversal, removes the damaged
base by a DNA glycosylase. The glycosylase removes the damaged base, creating a gap
in the sequence. DNA polymerase then fills in the gap with the correct base, and then the
break is ligated to the parental strand. Nucleotide excision repair differs from Base
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excision repair in that a larger segment of DNA is removed even if only one base is to be
corrected. Nucleotide excision is responsible for removal of most bulky adducts from
DNA. In this case, the DNA is unwo und at the site of repair producing a bubble.
Enzymes then remove the affected base and several bases surrounding it. Using the
opposite strand as a template, DNA polymerase fills in the excised nucleotides with
correct matches. DNA binds the new strand into the backbone.
Mismatch repair occurs after DNA replication and is a final check of the
sequence. It deals with correcting mismatches of normal bases formed during DNA
replication, genetic recombination, and as a result of DNA damage induced by chemical
and physical agents (Preston and Hoffmann 2001). The strand is checked for base pair
matches, using enzymes involved in excision repair and other specialized enzymes.
DNA strand breaks are corrected according to the type of break. Single-strand breaks are
corrected using the same systems as used in Base-Excision Repair. Double-strand breaks
are repaired via two methods: direct joining and homologous recomb ination. Direct
joining of the broken ends requires a protein that recognizes and binds the exposed ends,
finally bringing them together for ligating. Errors in direct joining are associated with
translocations that are associated with many cancers. Ho mologous recombination uses
information found in the sister chromatid, or a homologous chromosome, to repair the
break. Two proteins used in homologous recombination are encoded by the tumor
suppressor genes BRCA-1 and BRCA-2. Research has shown that inherited mutations in
either of these genes predispose women to breast cancer.
Tolerance mechanisms evade the damage without making repairs (Pitot and
Dragan 2001). If the damage in the DNA strand cannot be corrected immediately, it may
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be left. In the case of DNA damage, such as a pyrimidine dimer for example, DNA
synthesis may be blocked. DNA replication may be able to resume downstream of a
dimer, leaving a gap of single-stranded unreplicated DNA (Montelone 1998). If the cell
divides, by filling in the gap, the dimer may be carried on through cell division.
1.5

Genomic Instability
Genomic instability is characterized by an increased frequency of mutations such

that an instable genome results. Many pathways to genomic instability have been
established. Germ line mutations and somatic mutations have been implicated in
dysregulation of cell cycle controls. Cell cycle checkpoint systems are employed by the
cell to maintain genomic integrity and proper cellular function. In eukaryotes, two
checkpoints prevent chromosome segregation when DNA replication is inhibited or DNA
is damaged (Murakami and Nurse 2000). One of the checkpoints works before entry into
mitosis and the other before chromosome duplication. If the checkpoint systems are not
working properly, then full complements are not transferred to daughter cells during
replication.
In the event that a gene is mutated in the cell, or if a mutated gene is inherited our
diploid nature initially will minimize the impact, except for dominant cases (Anderson
2001). The cell will use the genetic information from the remaining normal allele. If the
normal allele is also lost, genomic damage is initiated. If severe damage is acquired in an
essential gene, the cell will go through a death pathway. If the damage is not severe
enough to initiate a death pathway then errors will continue to be made in the genome
resulting in increase instability.
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1.6

Carcinogenesis
Cancers acquire multiple genetic changes in DNA nucleotide sequence often

resulting in chromosomal abnormalities. Many cancers also undergo epigenetic changes
that can have profound effects on gene expression (Jones and Baylin 2002). It has been
suggested that the acquisition of some form of inherent genomic instability (defined as a
mutator phenotype of hypermutation) is a hallmark of tumorigenesis (Hanahan and
Weinberg 2000). It is assumed therefore, that genomic instability is the driving force
behind tumor formation. Arguments have been raised by some that genomic instability is
not necessary for tumorigenesis to occur. Sieber et. al. argue that early tumors grow
with a normal mutation rate (Sieber, Heinimann et al. 2003). Genomic instability is then
acquired and spreads throughout the tumor, therefore giving it its characteristic growth
advantage. Vogelstein presented a colorectal cancer progression pathway, which defined
cancer as a clear, well-defined process from normal to cancerous cells due to the
acquisition of genomic instability. Some believe cancer formation to be a much more
chaotic process, with many routes to genomic instability, undergoing many less
significant events. Factors such as genomic destabilization, Darwinian evolution, and
natural selection for invasive, proliferating populations of cells are the essence of cancer
(Anderson 2001).

1.7

Epigenetic Information
The three main types of epigenetic information are cytosine DNA methylation,

genomic imprinting, and histone modifications (Feinberg and Tycko 2004).
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1.8

Cytosine DNA Methylation
Methylation of cytosine is the only naturally occurring modification of DNA in

mammals (Moore, Huang et al. 2003) and is perhaps the most critical component of
epigenetic regulation in mammalian cells. In higher order mammals DNA methylation
usually occurs at CpG dinucleotides which are frequently clustered in regions of about 12kb in length. These CpG islands are located in or near the promoter and exon regions of
genes (Laird 1997; Jones and Laird 1999; Esteller and Herman 2002; Li, Hursting et al.
2003). Abnormal DNA methylation patterns are a hallmark of most cancers, including
those of high proportion in the United States such as colon, lung, prostate, and breast
cancer (Baylin, Herman et al. 1998; Esteller, Corn et al. 2001; Ross 2003). Common
characteristics of mammalian tumor cells include widespread global hypomethylation and
region specific hypomethylation and hypermethylation.
Cytosine methylation is catalyzed by one of three DNA transferases (DNMT1,
DNMT3A, DNMT3B), which transfer methyl groups from S-adenosylmethionines (SAM)
to the 5’ carbon of cytosine residues (Li, Hursting et al. 2003). DNMT1 is the most
abundant methyltransferase and is responsible for global DNA methylation after
replication. Figure 1.1 illustrates the mechanism of DNMT methylation via the SAM
pathway (Strathdee and Brown 2002).
Mechanisms for promoter hypemethylation and the resulting loss of gene
expression are being investigated. The thought is that de novo methylation initiates the
silencing of genes. The methylated gene then recruits methyl binding proteins (MBP)
and histone de-acetylases. A condensed chromatin structure results that silences the
associated gene.
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Cytosine

SAM-CH3
DNMT
SAM

5-Methylcytosine

Figure 1.1 The mechanism of DNMT methylation (Strathdee and Brown 2002).
1.8.1

Regional Hypomethylation

Loss of DNA methylation at CpG dinucleotides was the first epigenetic
abnormality to be identified in cancer cells (Feinberg and Tycko 2004).
Hypomethylation of DNA has been recognized to have mechanistic implications in the
genome.
Hypomethylation has been associated with cancer, by activating proto-oncogene.
Proto-oncogene are normally methylated and silenced within the genome. Cancer has
been associated with the activation of proto-oncogenes. The oncogene H-ras is a classic
example of a gene affected by hypomethylation (Feinberg and Tycko 2004). H-ras
encodes a protein that regulates signal transduction to the cell nucleus, regulating cell
division. A possible consequence of hypmethylation in the genome is genomic
instability, resulting in a loss of heterozygosity (LOH) (Chen, Pettersson et al. 1998).
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LOH is characterized by the loss of one allele at a specific locus (site on the
chromosome) which can activate proto-oncogenes.
1.8.2

Regional Hypermethylation.

Increased methylation is observed in the promoters of many genes in cancer cells
(Dunn 2003). This promoter methylation has been shown to correlate with inhibition of
transcription (Verma, Dunn et al. 2003) and the inactivation of tumor suppressor genes,
which correlates with cancer progression.
A small set of cellular genes are the targets for genetic alterations that initiate
neoplastic transformations (Gregus and Klaasen 2001). Tumor-suppressor genes are
crucial in the regulation of cell division. Tumor-suppressors encode proteins that inhibit
the progression of cells in the division cycle (Gregus and Klaasen 2001). Tumor
suppressors, unlike proto-oncogenes, are activated in the normal genome. When DNA
damage is detected by a tumor suppressor gene it can either halt cell division until the
damage is corrected, or stimulate the cells to go through an apoptotic pathway. When
tumor suppressors are not functioning correctly, cells proliferate in an uncontrolled
fashion accumulating further DNA damage. Inactivation of tumor suppression may be
accomplished by faulty nucleotide-excision repair, base-excision repair, mismatch repair,
chromosomal repair, or changes in the status of CpG- island methylation. A normal cell
has two alleles of a tumor suppressor gene. Most tumor suppressor genes are recessive
and must be inactivated by a two hit method, which disables both alleles. Knudsons’s
two-hit hypothesis is detailed in Fig. 1.2 (Jones and Laird 1999; Jain 2003). Inactivation
of tumor suppressor genes is associated with considerable tissue specificity for cancer
development (Pitot and Dragan 2001).
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The best recognized tumor suppressor involved in carcinogenesis is p53. The p53
gene is a tetramer that is an exception to the two- hit hypothesis. Because of its structure
it can be inactivated by one hit. p53 is activated in response to several malignancyassociated stress signals, resulting in the inhibition of tumor-cell growth (Balint and
Vousden 2001; Vousden and Lu 2002). p53 may respond to stress using a variety of
responses such as halt of cell proliferation, apoptosis, and repair of genetic damage.
Tumor mutations associated with p53 are almost completely single base substitutions.
Mutations in the p53 gene are found in fifty percent of human tumors and in a variety of
induced cancers (Gregus and Klaasen 2001).
1.9

Genomic Imprinting
Genomic imprinting is a parent-of-origin-specific allele silencing, or relative

silencing of one parental allele compared with the other parental allele (Feinberg and
Tycko 2004). DNA methylation is a vital molecular mechanism of imprinting. It is
DNA methylation that marks the imprinted genes differently on egg and sperm.
Inheritance of these epigenetic marks leads to differential gene expression (Reik, Collick
et al. 1987). The germ line has the role of resetting imprints such that in mature gametes
they reflect the sex of that germ line (Reik and Walter 2001).
A number of pediatric solid tumors are associated with LOH of genes that are
known to be imprinted in normal tissue (Dunn 2003). One mechanism for loss of
imprinting (LOI) is hypermethylation of the tumor suppressor and transcription regulator
H19 (Verona and Bartolomei 2003), which allows activation of the normally silent
maternal allele of IGF2 (Cui, Onyango et al. 2002).
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Figure 1.2 Knudson’s hypothesis. (Adapted Jones and Laird 1999)
1.10

Histone Modifications
The typical eukaryotic chromosome contains 1 to 20cm of DNA packed into a

dense structure called chromatin. Histones are proteins that aggregate with DNA to make
the basic structural subunit of chromatin which are called nucleosomes. The aminoterminal tails of histones protrude from the nucleosome and are subject to chemical
modifications including phosphorylation, acetylation, and methylation (Jenuwein and
Allis 2001; Kondo, Shen et al. 2003). The histone code uses chromatic location to
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determine the expression status of individual genes. Modifications may alter gene
expression by altering the regulatory factors associated with chromatin. DNA
methylation enables the conversion of histones to a nonacetylated state through histone
deacetylases (HDAC), which is thought to result in the production of compacted
chromatin that is resistant to transcription (Nan, Campoy et al. 1997; Nan, Ng et al.
1998).
Histone acetylation is maintained by a balance between the activities of two
enzyme families, the histone acetyltransferases and histone deacetylases (HDACs)
(Turner 1998). A lack of balance in the two enzymes can lead to changes in the genome.
The silencing of gene expression is associated with deacetylated histones, which are often
found to be associated with regions of DNA methylation as well as methylation at the
lysine 4 residue of histone 3 (Thiagalingam, Cheng et al. 2003). Histone H3- lysine 9
methylatio n has been associated with gene silencing in cancer cells of the tumor
suppressor genes p14ARF and p16INK4 (Nguyen, Weisenberger et al. 2002). Deathassociated protein kinase (DAPK) is a tumor suppressor associated with positive
regulation of apoptosis and tumor necrosis factors. DNA methylation and histone
deacetylation were found to be associated with silenced DAPK expression in colorectal
and gastric cancers (Satoh, Toyota et al. 2002).
1.11

Causes of Aberrant Methylation
Possible causes of atypical methylation within the genome are numerous. Links

to diet and the polymorphism of methylenetratrahydrofolate reductase (MTHFR) have
been established in increased colorectal cancer (Dunn, Verma et al. 2003; Feinberg and
Tycko 2004). Folate is an important mediator in methyl group metabolism, which is an
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important factor in the formation of methyl donor S-adenosylmethionine (SAM). A lack
of folate could result in hypomethylation. The resulting hypomethylation could
contribute to cancer risk by increasing the rate of chromosomal breakage caused by uracil
misincorporation during DNA synthesis or by decreasing DNA methylation (Herbert
1986; Moore, Huang et al. 2003).
De Novo methylation of genes is considered to be primarily an epigenetic event,
but methylation can also be influenced by exogenous factors. Many common
environmental carcinogens have been shown to alter DNA methylation patterns. An
association between nickel exposure, epigenetic silencing of the tumor suppressor gene
(p16), and tumorigenesis was reported (Sutherland and Costa 2003). Arsenic and other
elements, found in environmental settings induces hyper- and hypomethylation in vivo
(Moore, Huang et al. 2003). Chemotherapeutic agents (Moore, Huang et al. 2003),
tobacco smoke, and numerous viruses such as human papilloma virus (Muegge, Young et
al. 2003; Verma 2003) have all been associated with aberrant methylation and cancer.
1.12

Properties and Processes of the Epidermis
The epidermis is a stratified squamous epithelium consisting of four

biochemically and morphologically distinct layers (Serewko, Popa et al. 2002). The
basal layer consists of a single layer of proliferating keatinocytes attached to the
basement membrane. When the basal cells commit to terminal differentiation they
withdraw from the cell cycle and down regulate specific genes such as the cyclin
dependent kinase-1 (cdk-1.) These differentiating cells then pass into the suprabasal
layers to form the spinous and granular layers that express genes specific to
differentiating cells. The granular cells commit to apoptosis, thus forming the cross-
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linked envelope characteristic of the stratum corneum (Serewko, Popa et al. 2002). This
complex process requires the coordinated activation and repression of specific genes.
Disruption of cell differentiation is known to accompany neoplasia (Hartwell and Kastan
1994). Several pathways are present that can alter genes that regulate cellular processes,
such as growth regulation, apoptosis, and terminal differentiation (Serewko, Popa et al.
2002). Tumor suppressors and DNA repair genes are know to control such processes.
1.13

Lichen Sclerosus (LS)
Lichen sclerosus is a dermatologic inflammation affecting genital and perianal

areas. It is a chronic, destructive dermatosis with a predilection for the vulva (Carlson,
Lamb et al. 1998). LS is a non-contagious condition, which is classified into the general
category of vulvodynia (chronic vulvar pain). This non-neoplastic disorder is
characterized by a white thickening of the skin of the vulva, which eventually leads to
scaring and lesions. It is usually localized to the perineum, labia, fourchette, and clitoris,
and does not affect the vagina. Symptoms include pruritis (severe itching), burning pain,
dyspareunia (pain with intercourse), vaginal discharge, and anal or genital bleeding
(Loening- Baucke 1991). Most frequently, treatment involves the use of topical
corticosteroids. Persistence despite most medical treatments is problematic (Carlson,
Ambros et al. 1998).
Symptomatic vulvar lichen sclerosus typically affects peri- menopausal women
with a mean age of 54 years (Wallace 1971; Carlson, Ambros et al. 1998), but may also
affect prepubertal girls (Wallace 1971; Carlson, Ambros et al. 1998; Neill, Tatnall et al.
2002). The etiology of LS remains unknown, although infectious, genetic, and
autoimmune causes have been suggested (Nyirjesy 2002). Of particular concern in
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diseases such as LS is the importance of chronic inflammation and scarring in relation
oncogenesis (Carlson, Ambros et al. 1998). LS is know to have numerous macrophages
(Carlson and Edenhamn 2000) which could produce free radicals that are known
mutagens possibly leading to genetic or epigenetic alterations. Advancement to
squamous cell carcinoma (SCC) could occur via genetic instabilities in tumor suppressors
and other genes.
SCC is the most common malignancy described in involvement with LS. Reports
of squamous cell carcinoma arising from patients with LS in a clinical setting are
prevalent. Agreements between the two differ greatly. One such study found that the
magnitude of this risk is about 5% or less in patients with lifelong LS (Wallace 1971;
Derrick, Ridley et al. 2000; Neill, Tatnall et al. 2002). Another study conducted by
(Carlson, Ambros et al. 1998) found a higher incidence. It was found that of patients
with symptomatic LS, 21% developed invasive SCC. Of those developing SCC 9% were
preceded by vulvar intraepithelial neoplasia (VIN) which is a precursory lesion of SCC.
However, histological evaluations of SCC have found that about 60% occur on a
background of LS (Vilmer, Cavelier-Balloy et al. 1998), leading one to contemplate the
association between LS and oncogenesis.
1.14

Squamous Cell Carcinoma
Squamous cell carcinoma of the vulva is a cancerous tumor that can affect wo men

of all ages. Approximately 90% of vulvar tumors are squamous cell carcinoma (Canavan
and Cohen 2002). Its incidence is about one-eighth that of cervical carcinoma, but
increases as a function of age to a peak of 20 per 100,000 after age 75 (Mabuchi, Bross et
al. 1985; Brinton, Nasca et al. 1990). It is characterized by red, pink, or white nodules or
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plaques, appearing on the labia, clitoris, or the perineum. A wart-like or rough ulcerated
appearance is common. Symptoms are similar in nature to LS, but often more severe.
SCC is usually slow growing and may begin with a precancerous condition known as
vulvar intraepithelial neoplasia (VIN) or dysplasia (Carlson, Ambros et al. 1998).
There are two clinicopathological types of vulvar squamous cell carcinoma.
Human papillomavirus (HPV)-positive and HPV-negative, which can be distinguished to
some degree on routine histology (Scurry and Vanin 1997). Table 1.2 depicts the
characteristics of the two types (Crum 1992).
Table 1.2 Models of vulvar cancer (Adapted Crum, et al, 1992.)
Characteristic
Age

Type 1
Younger (35 to 65 years old)

Type 2
Older (55 to 85 years old)

Pre-existing lesion

Vulvar intraepithelial neoplasia

Vulvar inflammation, lichen
sclerosis, differentiated VIN

High association
Cervical neoplasia
Cofactors

HPV DNA
History of condyloma

Low association
Age, immune status, viral integration,
possibly mutated genes
Frequent (>60 percent)
Strong association

Vulvar atypia, possibly
mutated genes
Seldom (<15 percent)
Rare association

Strong association
History of STD
Cigarette smoking

1.15

Rare association
High incidence

Low incidence

Polymerase Chain Reaction
The polymerase chain reaction is a commonly used method in molecular genetics.

It is a powerful method by which a target sequence of nucleic acids may be amplified.
DNA sequences usually 50 to 2,000 nucleotides long are “selected” from an original
template such as genomic DNA using oligonucleotide primers. The DNA is amplified in
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a solution of reagents that enhance the effectiveness of amplification. PCR reactions
include taq DNA polymerase, MgCl2, PCR buffer, deoxynucleotide triphosphates
(dNTP’s), and template DNA. A DNA thermal cycler is used to provide varying
temperatures for the denaturation, annealing, and extension of the DNA sequences.
Amplification is carried out over numerous cycles to produce the desired number of
copies. Each DNA template produces one copy for each cycle. In the following cycle
the new strand along with its template act as a template, so in theory the DNA of interest
will double with each cycle performed. PCR will amplify DNA exponentially providing
the essential reagents and DNA are present.
Oligonucleotide (oligo) primers are necessary for polymerase chain reaction.
They are usually short sequences 20-30 nucleotides in total length that are created in a
laboratory. In standard PCR two primers are used. These primers, referred to as forward
and reverse are used to target the nucleotides at either end of the targeted DNA sequence.
Nested PCR adds a step to increase annealing efficiency which is especially
useful when final sequences of less than 200 base pair are expected. The two-stage
nested PCR approach improves the sensitivity to detect methylated alleles by greater than
50 fold over the original method (Palmisano, Divine et al. 2000). This first PCR uses
oligos that amplify a region of DNA that is slightly larger than the final product. This
region overlaps the final sequence by 50 to 100 base pair on both ends of the forward and
reverse primer. A second nested PCR is then run using the product from the first PCR as
template. This run actually produces the final section (gene) of interest. Figure 1.3
illustrates PCR.
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Figure 1.3 Polymerase Chain Reaction
1.16

Methylation Specific Polymerase Chain Reaction (MSP)
The most widely used assay for detecting methylation is methylation-specific

polymerase chain reaction (MSP), developed at The Johns Hopkins University (Herman,
Graff et al. 1996). This method involves the investigation of the CpG islands by utilizing
slight variations in traditional PCR methods. After isolation the DNA is treated with
sodium bisulfite to convert all unmethylated cytosines to uracils. Methylated cytosines
remain intact. PCR is then carried out using primers that are specific for either the
methylated or unmethylated DNA. If the primer has matched successfully then
amplification will occur. Electrophoresis is then used to resolve the amplification
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products on a 2-3% agarose gel. If methylation is present bands will be seen when
amplified with a methylated primer.

1.17

Gene Selection
The purpose of this study was to determine the correlation of vulvar cancer with

promoter methylation of selected genes. Based on published data MSP was chosen as an
effective means of evaluating the promoter region of tumor suppressors. Two tumor
suppressors and two DNA repair genes that are implicated with many types of cancer
were chosen for this study based on published data. The two tumor suppressors chosen
were p16 (INK4a) and p15 (INK4b). The two DNA repair genes selected were O6
methyl guanine methyl transferase (MGMT) and glutathione S-transferase pi (GSTP1).
Table 1.3 lists genes tha t are commonly affected by aberrant methylation.
1.17.1 p16 (INK4a) and p15 (INK4b)
Loss of cell cycle regulation through changes in the cyclin D/retionoblastoma
(pRb) pathway is common in human neoplasia (Carlson, Ambros et al. 1998; Wong
2001). p16 encodes cyclin-dependent kinase (CDK) inhibitors 4 and 6, which negatively
regulate G1-S transition of the proliferating cells by contributing to the maintenance of
pRb in an active state (Hartwell and Kastan 1994; Morgan 1995; Xing, Nie et al. 1999).
A lack of the p16 inhibitory effect on CDK enzymes predisposes cells to
uncontrolled growth. Previous work on epigenetic silencing of p16(INK4a) in vulva
disorders detected aberrant methylation in 68% of VC, 69.2% of VIN, and 42.8% of LS
cases (Lerma, Esteller et al. 2002) using MSPCR. Another study found p16 silenced in
36% of vulvar SCC cases (Gasco, Sullivan et al. 2002). Epigenetic inactivation most
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likely represents an early event that may occur in clinically benign lesions such as LS
(Lerma, Esteller et al. 2002).
p15 has much in common with it’s sibling p16. It is not only adjacent to p16 on
chromosome 9p21, but it also encodes a cyclin-dependent kinase inhibor. p15 is unlike
p16 in that it is pRb independent. Its mode of action is to bind to the CDK enzyme
preventing p27 association (Xing, Nie et al. 1999). p27 then binds to and inactivates the
cyclin E-CDK2 complex, thereby blockin the cell cycle at the G1-S boundary
(Reynisdottir and Massague 1997).
1.17.2 O6 Methyl Guanine Methyl Transferase (MGMT)
MGMT plays a critical role in DNA repair pathways by removing alkyl adducts
from methyl groups. The MGMT DNA repair protein is responsible for the removal of
mutagenic and cytotoxic adducts from the O6 position of guanine (Esteller, Toyota et al.
2000). O6 -methylguanine creates a mispair with thymine during DNA replication and if
the adduct is not removed a conversion from a GàC pair to an AàT pair results
(Esteller, Toyota et al. 2000). The loss of expression however, is almost always due to
epigenetic silencing of the gene via methylation pathways.
1.17.3 Glutathione S-transferase pi (GSTP1)
GST genes comprise many isoenzymes that are essential in cellular protection
against mutagenic and carcinogenic agents. Repression of transcription accompanying
CpG island hypermethylation has been predisposed to be mediated by methyl-CpG
binding domain (MBG) proteins (Bakker, Lin et al. 2002). In essence the MBG protein
competes for access to the promoter region of the gene so that the GSTP1 encoded
protein cannot bind.
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Table 1.3 Genes affected by CpG methylation.
Gene

Function

Associated Tumor
Types

Notes

p16

Encode cyclin-dependent
kinase inhibitors, which
regulate G1 -S transition,
associated with aberrant p53
expression and associated
apoptosis

Lung (non-small cell
lung cancer), vulvar,
colon, lymphomas,
bladder, esophagus,
stomach, renal, others

Epigenetic factors
more significant than
genetic mutations

p15

Encode cyclin-dependent
kinase inhibitors, which
regulate G1 -S transition.
Independent of pRb

Acute myeloid
leukemia, Acute
lymphoblastic
leukemia,
glioblastoma brain
cancer, colon, lung,
breast, others

p15 is located on
chromosome 9p21
with p16, but
methylation of both
genes is rare

GSTP1

Enzymes involved in the
detoxification of xenobiotics
and oxygen radicals, may
help defend hepatocytes
against reactive oxygen
species

Prostate, liver, colon,
breast, kidney, others

Located on
chromosome 11q13,
not traditionally
considered to be a
tumor suppressor, but
high levels of
hypermethylation are
found in solid tumors

MGMT

DNA repair protein, which
removes alkyl adducts from a
methyl group to an active
cytosine in its own sequence.
The reaction inactivates the
MGMT molecule for each
lesion repaired

Brain, head and neck,
breast, prostate,
renal, colon, nonHodgkin’s lymphoma,
others

Associated with the
DNA
methyltransferase
deficient phenotype,
Increased K-ras
mutation

INK4a
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CHAPTER 2
MATERIALS AND METHODS

2.1

Genomic DNA
Normal and tumor vulvar tissues were obtained via radical vulvectomies from

over 100 patients. Due to the nature of a radical vulvectomy surrounding normal tissues,
lichen sclerosis tissues, and other tissue types were obtained when in close proximity to
the squamous cell tissue. In addition to the collection of tumor and the associated
surrounding tissue normal tissue was collected from five patients with no apparent vulvar
ailment. This gave the opportunity to evaluate true normal tissue as an unmethylated
same tissue control. The patient tissues were histologically evaluated by Dr. Andrew
Carlson of Albany Medical College and the corresponding histological condition was
noted. The tissues for each patient were then separated according to condition and
packaged for various analyses. Tissues that were to be analyzed in by us were stored at 80C and shipped on dry ice. Upon arrival the samples were again placed in a freezer at 80C. Dr. Carlson has analyzed the tissues for protein expression and will be comparing
this data with the corresponding methylation data.
2.2

DNA Isolation
DNA was isolated from the specimens by standard phenol and chloroform

extraction procedures (Xing, Nie et al. 1999). This protocol is the most commonly used
method of purifying and concentrating DNA preparations. Approximately 500 mg of
tissue was minced and then frozen in liquid nitrogen. The tissue was then crushed under
liquid nitrogen using a mortar and pestle until a fine powder was obtained. The tissue
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was then suspended in digestion buffer to approximately 1mL and left to digest at 50°C
for 12 hours in capped tubes. The digest was extracted with phenol chloroform and cold
ethanol. The DNA precipitates were then centrifuged and the supernatant containing the
DNA was collected.
The second method used for genomic DNA extraction was the QIAamp DNA
Mini Kit (Qiagen). The QIAamp kit was used as an efficient and quicker alternative
which was useful due to the large number of samples that were isolated. The samples
were then cleaned using standard ethanol precipitation and re-suspended in TE buffer.
2.2.1

DNA Quantification

Spectrophotometric detection is the most widely used method to determine DNA
concentration(Adams 2003). The isolated DNA was analyzed for concentration and
purity using a Cary 100 Bio spectrophotometer. Of the various methods is the calculation
of the ratio of absorbance at 260 nm to the absorbance at 280 nm with a 1cm path length.
The ratio is used to approximate the percentage of absorbing molecules in the sample that
are protein. A sample of pure nucleic acid will have an absorbance ratio of 1.95. Pure
protein on the other hand will absorb at 0.57. For this study the sample absorbances all
fell very close to the 1.9 value, which confirms a relatively pure nucleic acid sample.
2.3

Bisulfite Modification
Approximately 2µg of DNA was denatured in a final concentration of 0.2M

NaOH for 10 min. at 37C to create single stranded DNA. Thirty microliters of 10mM
hydroquinone and 520 µl of freshly prepared 3M sodium bisulfite (pH 5.0) was added,
then samples were covered with mineral oil and and incubated at 50C for 16 hours. The
DNA was then purified using the Wizard DNA purification kit (Promega) and
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resuspended in 50ul of heated water (60-70C). NaOH was added to a final concentration
of 0.3M and glycogen (Boehringer) was used as a carrier. DNA was then ethanol
precipitated as normal and resuspended in 20µl of water. Samples were stored at -80C
until use.
2.4

Reagents
Reagents were chosen based on peer reviews of publications from labs that

employ the methylation specific polymerase chain reaction assay (MSP). Amplitaq Gold
(Applied Biosystems) is the thermostable taq polymerase that was chosen for the assay.
This polymerase is often used in sensitive applications to reduce all possibility of nonspecific annealing of primers which might cause false positive results. The primers used
in the assay were purchased from BioServe Biotechnologies (Laurel, MD). Primers were
diluted upon arrival with TE buffer to 0.5 nano moles per microliter. The four dNTP’s
used in were diluted in water to a working concentration of 25mM each. Unmethylated
and methylated controls were purchased from Serologicals Corporation (United
Kingdom). All reagents were stored in a standard freezer at -20C and thawed on ice
before use.
2.5

Methylation Specific PCR Primer Selection
Gene sequences were obtained by searching the PubMed nucleotide database,

which is a service of the National Library of Medicine
(http://www.ncbi.nlm.nih.gov/PubMed/.)
Nested PCR was chosen as the method of choice for three of the four sites. This
“two stage” PCR approach improves the sensitivity to detect methylated alleles by greater
than 50 fold over the original method (one methylated allele in greater than 50,000
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methylated alleles) (Palmisano, Divine et al. 2000). The two nested primers recognize
the bisulfite- modified template but do not discriminate between the methylated and
unmethylated alleles. It in essence “cradles” the final sequence allowing for improved
final amplification. The nested primers for p16 and MGMT were reported previously by
(Palmisano, Divine et al. 2000). The GSTP1 nested primer was chosen by analyzing the
area around the bisulfite- modified sequence and choosing a length twenty to twenty five
nucleotides still within the promoter region of the gene.
For MSP, two pairs of primers are needed, one of them specific for the bisulfitemodified / methylated DNA (M pair) and one for the modified / unmethylated DNA (U
pair.) For each sample two PCR’s must be performed with each pair of primers.
Amplification with the U pair indicates no methylation of the CpG island. Amplification
with the M pair and amplification with both M and U pairs indicates methylation. Primer
sequences for the amplification of methylated and unmethylated alleles of p16 (Herman,
Graff et al. 1996), MGMT (Esteller, Toyota et al. 2000), and GSTP1 (Esteller, Corn et al.
1998) were chosen based on published data. Primer sequences for the methylated and
unmethylated alleles of p15 were originally obtained from a published source, but
amplification lacked specificity. Table 2.1 lists primer names, sequences, product base
pair size, annealing temperatures, and sources.
MethPrimer (Li and Dahiya 2002) was used to design new primers for the p15
amplification site (http://www.ucsf.edu/urogene/methprimer/). MethPrimer, which is
based on Primer3, is a program designed for the production of MSP primers. It takes a
DNA sequence as its input and searches the sequence for CpG islands (Li and Dahiya
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2002). Primers are then picked within the CpG island based on four factors (Li and
Dahiya 2002).
1. Primers should contain at least one CpG site at the most 3’-end. By default
one of the three bases at the end must be a CpG ‘C’. This can be edited by the
user within the program by changing the number of bases from the end that
the CpG ‘C’ will be located.
2. Multiple CpG sites in both primers are preferred.
3. Primers in the M pair and U pair should contain the same CpG sites within
their sequence. For example if the forward M primer is ATT TAG TTT CGT
TTA AGG TTC GA, the forward U primer must also contain the two CpG
sites (underlined) as in the M pair, but with the 5 methyl Cytosine replaced by
‘T’.
4. Two sets of primers should preferably have similar Tm values, thus allowing
the two PCR reactions for each sample to be carried out in the same PCR
machine under the same annealing conditions.
2.6

Methylation Specific PCR Amplification
The PCR reaction mixture contained .625U Taq polymerase, 1X PCR buffer,

3.0mM MgCl2 , dNTP’s (each at 1.25mM), primers (1µM final), .01% cresol red rediload, and bisulfite- modified DNA (50ng) in a final volume of 25µl. 0.2ml 96 well, thin
wall reaction plates were used for each PCR. Primer attributes are described in table 2.1.
PCR amplification was carried out using a GeneAmp PCR System 9700 (Applied
Biosystems). Initial denaturation at 95C for 9 minutes is required to activate the
thermostable Amplitaq Gold prior to amplification. Nested amplification parameters
were similar to the final PCR with the annealing temperature being the exception. PCR
reactions were carried out for 30 cycles (1 minute at 95C, 1 minute at the annealing
temperature listed below, 1 minute at 72C), followed by a 7 minute final extension at
72C.
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Table 2.1 Primer Data.
Primer set

Sense primer, 5’ à 3’

Antisense primer, 5’ à 3’

Size, bp

p16-T

GAAGAAAGAGGAG
GGGTTGG

CTACAAACCCTCTAC
CCACC

279

Anneal
temp., C
55

p16-M

TTATTAGAGGGTGG
GGCGGATCGC
TTATTAGAGGGTGG
GGTGGATTGT
GGATATGTTGGGAT
AGTT

GACCCCGAACCGCGA
CCGTAA
CAACCCCAAACCACA
ACCATAA
CCAAAAACCCCAAAC
CC

156

62

151

62

289

55

TTTGTGTTTTGATGT
TTGTAGGTTTTTGT
TTTCGACGTTCGTA
GGTTTTCGC
GGATTTTAGGGCGT
TTTTTT

AACTCCACACTCTTC
CAAAAACAAAACA
GCACTCTTCCGAAAA
CGAAACG
CCGAACCTTATAAAA
ATAATCCC

93

62

81

62

154

57

GATGTTTGGGGTGT
AGTGGTTGTT
TTCGGGGTGTAGCG
GTCGTC
TGTGATGTGTTTGT
ATTTTGTGGTT
GCGTTCGTATTTTG
CGGTT

CCACCCCAATACTAA
ATCACAACA
GCCCCAATACTAAAT
CACGACG
CCATACAATAACCAA
ACAACCAA
CGTACAATAACCGAA
CGACCGA

97

67

91

67

199

62

200

62

p16-U
MGMT-T

MGMT-U
MGMTM
GSTP1-T

GSTP1-U
GSTP1-M
p15-U
p15-M

2.7

Reference
(Palmisano,
Divine et al.
2000)
(Herman, Graff
et al. 1996)
(Herman, Graff
et al. 1996)
(Palmisano,
Divine et al.
2000)
(Esteller, Toyota
et al. 2000)
(Esteller, Toyota
et al. 2000)
Wilson and
Hutchinson
Design
(Esteller, Corn et
al. 1998)
(Esteller, Corn et
al. 1998)
Methprimer
Design
Methprimer
Design

Agarose Gel Electrophoresis
PCR product (11.5ul) containing sucrose loading dye and .01% cresol red was

directly loaded onto a 2% TBE agarose gel using a multipipetor. The TBE gels contained
0.5 µg per mL Ethidium Bromide solutio n for UV visualization. The cresol red loading
dye acts as a visual detector and adds weight to the sample so that it will sink to the
bottom of the agarose gel wells. Gels were run on a BioRad Sub Cell GT 2 at 150 Volts
for 70 minutes. The gels were then removed and placed on a BioRad Gel Doc imager
and exposed to ultra violet light for analysis and image capture.
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CHAPTER 3
RESULTS

3.1

Introduction
Four tumor suppressor genes that are commonly associated with inactivation by

epigenetic instability leading to subsequent human cancer were analyzed by methylation
specific polymerase chain reaction (MSP.) Vulvar SCC, adjacent LS, adjacent normal
tissue, and unassociated normal tissues from radical vulvectomies were examined to
establish an etiological model of disease. To determine associations between tumor
suppressor inactivation and human vulvar cancer the following genes were studied: p16,
p15, GSTP1, and MGMT.
3.2

MSP Standards
Water blanks were included in each MSP reaction to eliminate the possibility of

reagent contamination. Universally unmethylated and methylated genomic DNA
standards were also included in each to assure specificity of MSP product. Unmethylated
standards were those that exhibited amplification with the unmethylated (U) primer from
the analyzed gene, therefore a band will appear at the appropriate size in the agarose gel.
Amplification does not occur in the presence of the methylated (M) primers. Methylated
standards are those that exhibit amplification in the presence of the M primers and not the
U primers.
3.3

Samples
NV specimens were collected from one individual exhibiting a normal

histological evaluation. Samples designated CW are those from individuals with
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histological types associated with cancer (SCC), lichen sclerosis (LS), and normal
adjacent tissues. The sub-grouping (last number in the sequence) is an identifier used to
discriminate multiple tissues taken from one patient.
3.4

Interpreting MSP Results
Those samples that were unmethylated were confirmed if amplification occurred

with the unmethylated (U) primer only. Therefore, a single band of the appropriate size
was seen in the unmethylated lane upon running the agarose gel. Positive methylation of
the four genes analyzed was confirmed if both primers M and U amplified the template
DNA resulting in a band in both the unmethylated and methylated lanes. This ‘partial
methylation’ is observed in many tumor types (Herman, Graff et al. 1996). Two DNA
samples would not amplify with any of the DNA primers so they were withdrawn from
the study. Complete non-amplifications were most likely due to a small tissue amounts
prior to genomic DNA isolation. Representative samples that tested positive for
methylation were analyzed a second time to ensure reproducibility.
Those samples that amplified in one or more genes, but would not amplify in all
four were analyzed two times to insure that template was incorporated into the MSP
reaction. This lack of amplification could be due to many factors. One is that both
alleles in the DNA of the withdrawn sample could have been permanently deleted. The
other explanation is that degradation could have occurred in the sample that inhibited
amplification of the template. SCC samples exhibited this phenomenon most prevalently,
which tends to point to the first explanation. Although interesting further study using
different methods would be required to justify allelic deletion.
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3.5

Statistical Analysis
A contingency table shows numerically the results of an experiment in which the

outcome is a categorical variable. Commonly, two groups of subjects are studied and
there are two possible outcomes. In this case the groups analyzed were SCC vs. normal
and SCC vs. LS, with possible outcomes being methylated and unmethylated. 2x2
contingency tables such as this, are best analyzed by a procedure very commonly called
the Fisher exact test (Zar 1999). A p value which is equal to or less than 0.05 is
considered to demonstrate a statistically significant difference between sets of samples.
3.6

p16 Gene
MSP amplification of the p16 gene was achieved by nested PCR. The outside

PCR yielded a product that was 279 base pair. p16 methylated primers and p16
unmethylated primers produced products that were of 156 base pair and 151 base pair in
length, respectively.
MSP analysis of the 157 samples analyzed for p16 revealed methylation in thirty
one samples. Methylation was found in nineteen of seventy three (26%) cases of vulvar
SCC. Lichen sclerosis also seemed informative in p16 yielding methylation in twelve of
fifty five (22%) cases. None of the eighteen normal adjacent tissues or the nine normal
unassociated tissues revealed methylation.
The methylation of SCC specimens using the p16 primer was found to be
significantly higher than normal tissues (p=0.0013). The occurrence of methylation in
adjacent lichen sclerosis tissues were also found to be significantly different from normal
tissues (p=0.0085). This relationship showing increased methylation from normal to LS
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suggests that epigenetic silencing of p16 is an early event in vulval neoplasia.
Representative examples of p16 MSP are illustrated in figure 3.1.

Figure 3.1 Representative samples of MSP analysis of the p16 gene.
Five cases (patient specimens CW40, CW41, CW44, CW49, and CW70) were
analyzed for progression of normal vulva to LS, and finally to SCC. In case 40 there was
no progression of methylation from normal to SCC. Cases CW41, CW44, and CW70
exhibited methylation in SCC, but no methylation in normal or LS samples. Patient
CW49 showed no methylation in normal tissues, but methylation in both LS and SCC
samples. Several of these samples were run numerous times for validation. Table 3.1
illustrates the results of these analyses for the five complete cases.
Table 3.1 Progression from normal to SCC for p16
Specimen
Identifier
p16 Status
CW 40-4
CW 40-5
CW 40-1
CW 40-2
CW 41-2
CW 41-4
CW 41-1
CW 44-1
CW 44-3
CW 44-4
CW 44-6
CW 44-2
CW 49-7
CW 49-4
CW 49-5
CW 49-6

N
LS
SCC
SCC
N
LS
SCC
N
LS
LS
LS
SCC
N
LS
LS
LS

+
+
+
+
+
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(Table 3.1 Continued)
Specimen
CW 49-1
CW 49-3
CW 70-7
CW 70-1
CW 70-4
CW 70-5
CW 70-6
CW 70-3
CW 70-2

+
–

Methylated
Unmethylated

3.7

p15 Gene

Identifier

p16 Status

SCC
SCC
N
LS
LS
LS
LS
SCC
SCC

+
+
+
+

Amplification of the p15 promoter region was accomplished using a non-nested
MSP reaction. The bioinformatics software MethPrimer was used to design appropriate
primers that would provide consistent amplification. The unmethylated and methylated
p15 amplification products were 199 and 200 base pair respectively.
MSP analysis of the p15 gene revealed thirty nine cases of methylation out of a
total one hundred thirty nine samples analyzed. Of the SCC samples analyzed, twenty
two of the sixty four (34%) exhibited methylation. In LS samples fifteen of forty eight
(31%) were positive for methylation. Two of the twenty five (8%) normal samples were
methylated. Of the normal tissues exhibiting methylation all ten unassociated normal
samples were unmethylated. Representative results are shown in Figure 3.2.
p15 methylation of SCC carcinoma tissues was significantly different than normal
tissues (p=0.0085). The associated LS tissue was also found to be significantly different
than that of normal tissues (p=0.0217). As with p16 the methylation trend from SCC to
LS suggests and early silencing event of the p15 marker in vulval neoplasia. It is
noteworthy that the methylation in the normal samples was observed in the cancer
associated normal tissues only.
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Figure 3.2 Representative samples of MSP analysis of the p15 gene.
Four cases that contained all three histological types were analyzed for p15
promoter methylation. None of the specimens analyzed for the patients CW30, CW44,
CW49, or CW70 displayed of methylation in the adjacent normal tissues. Interestingly,
patient CW 49 SCC tissue did not harbor a methylated p15 gene, but did display
methylation in one of two LS specimens. The methylation data for these four samples is
reported in table 3.3.
Table 3.2 Progression from normal to SCC for p15
Specimen
Identifier
p15 Status
CW 30-2
CW 30-3
CW 30-4
CW 30-5
CW 30-1
CW 44-1
CW 44-6
CW 44-3
CW 44-4
CW 44-2
CW 49-7
CW 49-4
CW 49-5
CW 49-1

N
LS
LS
LS
SCC
N
LS
LS
LS
SCC
N
LS
LS
SCC

+
+
+
+
-
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Table 3.2 (Continued)
Specimen
CW 49-3
CW 70-7
CW 70-1
CW 70-5
CW 70-6
CW 70-3
CW 70-2

+
–

Methylated
Unmethylated

3.8

GSTP1 Gene

Identifier

p15 Status

SCC
N
LS
LS
LS
SCC
SCC

+
+

Amplification of the GSTP1 promoter sequence was accomplished using the
nested MSP approach. The outside primers resulted in a 154 base pair DNA fragment,
while the U primer and M primer yielded a 97 and 91 base pair fragment.
Sample analysis of the GS TP1 promoter following MSP revealed a total of fourteen
methylated samples of a total one hundred forty four analyzed. Four (6%) of the sixty
nine samples tested for SCC yielded methylation. Samples with LS histology were found
methylated in seven of forty eight total cases (15%). Two (7%) of the twenty eight total
normal samples analyzed were methylated. The ten normal associated samples that were
analyzed contained no methylation.
SCC tissue at the GSTP1 promoter were not found to be statistically significant
from the normal tissue samples analyzed (p=1.0000). When LS tissues were compared to
the normal tissues again no significant difference in the two were found (p=0.4717).
Furthermore, when excluding the normal adjacent tissues from the analysis the same
trend was observed. There was no statistically significant difference observed between
the SCC and normal unassociated groups (p=1.0000) or the LS and normal unassociated
groups (p=0.0591). GSTP1 proves to be a poor indicator of cancer due to low
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methylation in cancer cells. Representative examples of the analysis of methylation from
the three tissue types are illustrated in figure 3.3.

Figure 3.3 Representative samples of MSP analysis of the GSTP1 gene.
No apparent trend in progression from normal to SCC tissues was observed in
four of the specimens that were examined that had all three histological types. The
methylation data for these four samples is reported in Table 3.4.
Table 3.3 Progression from normal to SCC for GSTP1
Specimen
Identifier
GSTP1 Status
CW 41-2
CW 41-4
CW 41-1
CW 44-1
CW 44-6
CW 44-3
CW 44-4
CW 44-2
CW 49-7
CW 49-5
CW 49-1
CW 49-3
CW 70-7
CW 70-1
CW 70-5
CW 70-6
CW 70-3
CW 70-2

N
LS
SCC
N
LS
LS
LS
SCC
N
LS
SCC
SCC
N
LS
LS
LS
SCC
SCC

+
+
+
-
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MGMT Gene
Identical nested PCR to that of the John’s Hopkins group led by James G. Herman
(Palmisano, Divine et al. 2000) was employed in the study that resulted in a 289 base pair
outside fragment and a 93 and 81 unmethylated and methylated fragment. SCC exhibited
the highest methylation with half of the seventy samples that were analyzed displaying
methylation. LS tissues were similar with twenty three of the forty nine aberrantly
methylated (47%). Of the twenty seven normal tissues analyzed twelve were methylated
(44%). Of the normal unassociated tissues (normal associated) in this study five of the
ten were methylated (50%) This corroborates with studies from other labs that indicate a
high degree of methylation in normal tissues (Eads, Lord et al. 2001). The data for
MGMT failed to reveal any significant difference in the methylation status between
histological types. Representative examples of the analysis of methylation from the three
tissue types are illustrated in figure 3.4.

Figure 3.4 Representative samples of MSP analysis of the MGMT gene.
Four cases were analyzed that displayed all three histological types, as presented
in Table 3.4. With the MGMT gene no correlation could be seen from normal tissue to
progression of SCC.
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Table 3.4 Progression from normal to SCC for MGMT
Specimen
Identifier
MGMT Status
CW 41-2
CW 41-4
CW 41-1
CW 44-1
CW 44-6
CW 44-3
CW 44-4
CW 44-2
CW 49-7
CW 49-5
CW 49-1
CW 49-3
CW 70-7
CW 70-1
CW 70-5
CW 70-6
CW 70-3
CW 70-2

3.10

N
LS
SCC
N
LS
LS
LS
SCC
N
LS
SCC
SCC
N
LS
LS
LS
SCC
SCC

+
+
+
+
+
+
+
+
+

Overall Results
It was found that p16 and p15 were promising in detecting aberrant methylation in

both SCC and LS samples. Of the two p16 was most advantageous exhibiting a
significant difference in methylation between SCC and normal tissues (normal adjacent
and unassociated normal) (p=0.0014). A significant difference in methylation between
LS and normal tissues were also observed (p=0.0075). p15 was also informative
displaying a significant difference in SCC and normal tissues (p=0.0045) and LS and
normal tissues (p=0.0028).
No significant difference was found in the methylation status of either GSTP1 or
MGMT genes. GSTP1 was found to have a low occurrence of methylation in all tissues.
MGMT was unusual in that the overall methylation was unexpectedly high in all tissues
tested. The results of all methylation tests conducted in this study are listed below in
table 3.5.
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Table 3.5 Results from methylation analysis from all tissues examined.
Specimen
NV-1A
NV-1B
NV-2C
NV-3A
NV-3B
NV-3C
NV-4A
NV-4B
NV-4C
NV-5
CW A-1
CW C-1
CW 1-1
CW 2-2
CW 2-3
CW 5-1
CW 6-5
CW 7-1
CW 10-1
CW 11-1
CW 12-1
CW 12-2
CW 12-4
CW 13-4
CW 13-5
CW 14-1
CW 14-2
CW 15-1
CW 15-2
CW 15-3
CW 16-3
CW 17-1
CW 17-2
CW 17-4
CW 17-6
CW 18-1
CW 18-2
CW 18-3
CW 18-4
CW 18-6
CW 19-1
CW 19-2
CW 21-1
CW 21-2
CW 21-3
CW 21-4

Identifier
N
N
N
N
N
N
N
N
N
N
SCC
SCC
SCC
LS
SCC
SCC
LS
SCC
SCC
SCC
SCC
SCC
SCC
N
N
SCC
SCC
SCC
SCC
LS
N
SCC
LS
LS
LS
SCC
SCC
SCC
SCC
SCC
SCC
SCC
SCC
LS
LS
LS

p16
ND
ND
ND
+
ND
ND
+
+
+
+
-
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p15
ND
ND
ND
ND
ND
ND
ND
ND
+
ND
+
+
+
ND
ND
ND
ND
+
+
+

MGMT
+
+
+
+
+
ND
ND
ND
ND
ND
ND
ND
+
ND
+
+
+
+
+
ND
+
-

GSTP1
ND
ND
ND
ND
ND
+
ND
+
+
ND
ND
ND
-

(Table 3.5 Continued)
Specimen
CW 22-3
CW 22-4
CW 23-3
CW 25-1
CW 25-3
CW 27-2
CW 28-1
CW 28-5
CW 29-2
CW 29-4
CW 29-5
CW 29-6
CW 29-7
CW 30-1
CW 30-2
CW 30-3
CW 30-4
CW 30-5
CW 31-3
CW 32-1
CW 34-1
CW 34-2
CW 34-3
CW 35-1
CW 35-2
CW 35-3
CW 35-5
CW 35-6
CW 35-7
CW 39-2
CW 40-1
CW 40-2
CW 40-4
CW 40-5
CW 41-1
CW 41-2
CW 41-4
CW 43-1
CW 43-4
CW 44-1
CW 44-2
CW 44-3
CW 44-4
CW 44-6
CW 45-4
CW 45-5

Identifier
LS
LS
N
SCC
LS
SCC
SCC
LS
SCC
LS
LS
SCC
LS
SCC
N
LS
LS
LS
LS
SCC
LS
SCC
LS
LS
LS
SCC
LS
LS
LS
SCC
SCC
SCC
N
LS
SCC
N
LS
SCC
SCC
N
SCC
LS
LS
LS
N
LS

p16
+
+
+
ND
+
ND
+
+
+
+
+
-
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p15
ND
+
+
ND
ND
+
ND
ND
+
+
ND
ND
ND
+
+
+
+
+
+

MGMT
ND
+
ND
+
ND
ND
ND
ND
+
ND
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-

GSTP1
ND
ND
ND
ND
ND
+
+
+
+
ND
ND
-

(Table 3.5 Continued)
Specimen
CW 46-3
CW 46-4
CW 46-6
CW 47-2
CW 47-3
CW 47-4
CW 49-1
CW 49-3
CW 49-4
CW 49-5
CW 49-6
CW 49-7
CW 50-1
CW 50-2
CW 50-4
CW 50-5
CW 50-6
CW 50-7
CW 52-1
CW 52-2
CW 52-4
CW 52-6
CW 53-1
CW 53-2
CW 57-1
CW 57-3
CW 60-1
CW 61-2
CW 61-4
CW 61-6
CW 62-1
CW 63-1
CW 63-2
CW 63-5
CW 64-3
CW 66-3
CW 66-4
CW 67-2
CW 70-1
CW 70-2
CW 70-3
CW 70-4
CW 70-5
CW 70-6
CW 70-7
CW 72-1

Identifier
LS
LS
LS
SCC
LS
LS
SCC
SCC
LS
LS
LS
N
SCC
SCC
SCC
LS
SCC
SCC
LS
N
LS
LS
LS
LS
SCC
N
N
LS
LS
SCC
N
SCC
SCC
SCC
SCC
LS
LS
N
LS
SCC
SCC
LS
LS
LS
N
SCC

p16
+
+
+
+
+
+
+
+
+
ND
+
+
+
+
+
ND
+
+
-
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p15
+
ND
ND
+
+
+
+
+
+
+
+
ND
+
+
ND
+
+
ND
-

MGMT
+
+
+
ND
+
ND
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
ND
+
+
+
+

GSTP1
ND
+
ND
ND
ND
+
ND
ND
+
+
-

(Table 3.5 Continued)
Specimen
CW 73-1
CW 73-4
CW 78-1
CW 78-2
CW 78-3
CW 78-4
CW 78-5
CW 79-1
CW 79-2
CW 79-3
CW 80-2
CW 89-1
CW 89-2
CW 89-3
CW 91-1
CW 91-2
CW 91-5
CW 93-1
CW 93-2
CW 96-1
CW 96-2
CW 97-1
CW 97-5
CW 98-1
CW 108-1
CW 108-2
CW 109-1
CW 109-2
CW 110-1
CW 110-3

Identifier
N
N
SCC
SCC
SCC
SCC
SCC
SCC
SCC
N
SCC
SCC
SCC
LS
SCC
SCC
LS
SCC
SCC
SCC
SCC
SCC
SCC
SCC
N
LS
SCC
SCC
SCC
SCC

p16
ND
+
ND
-

p15
+
ND
+
+
+
+
ND
+
+
+
ND
-

MGMT
ND
+
+
+
+
+
+
+
+
+
+
+
+
ND
+
+
+
+
+
+

GSTP1
ND
+
+
ND
-

Samples designated + were found to be methylated.
Samples designated – were found to be unmethylated.
Samples designated ND were not determined.
This study found significant differences in the methylation patterns of the
two genes analyzed. The statistically significant differences of p16 and p15 were
observed between SCC and normal samples as well as between LS and normal samples.
These statistically significant relationships of increased methylation among tissues are
very powerful. The data suggest that that epigenetic silencing of p16 and p15 is an early
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event in vulvar neoplasia. Tables 3.6, 3.7, and 3.8 summarize the significant differences
between the various histological types.
Table 3.6 Statistical comparison of SCC and total normal samples
Gene
SCC
Normal
P Value
p16
26.0 %
0%
0.0013
p15
34.4 %
7.4 %
0.0085
GSTP1
5.8 %
7.1 %
1.0000
MGMT
50.0 %
44.4 %
0.6567

P<0.05
Yes
Yes
No
No

Table 3.7 Statistical comparison of LS and total normal samples
Gene
LS
Normal
P Value
p16
21.8 %
0%
0.0065
p15
31.3 %
7.4 %
0.0217
GSTP1
14.6 %
7.1 %
0.4717
MGMT
46.9 %
44.4 %
1.0000

P<0.05
Yes
Yes
No
No

Table 3.8 Statistical comparison of SCC and LS samples
Gene
SCC
LS
P Value
p16
26.0 %
21.8 %
0.6785
p15
34.4 %
31.3 %
0.8397
GSTP1
5.8 %
14.6 %
0.1221
MGMT
50.0 %
46.9 %
0.8525

P<0.05
No
No
No
No

Table 3.9 Statistical comparison of SCC and unassociated normal samples for those
samples with methylated adjacent normal samples
Gene
SCC
Normal
P Value
P<0.05
p16
26.0%
0%
0.1084
No
p15
34.4 %
0%
0.0279
Yes
GSTP1
5.8 %
0%
1.0000
No
MGMT
50.0 %
50 %
1.0000
No
Samples were compared among the four genes that were tested. Two of the
possible sixty one SCC sample displayed methylation in three genes (3.3%). Nineteen
SCC samples had methylation in two or three genes (27.5%), and fifty two of the SCC
samples had methylation in one or more genes (68.4%).
One LS sample (CW 49-5) was found that displayed aberrant methylation in all
four genes. Four samples presented methylation in three genes or more out of a total
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forty nine for 7.1%. Fourteen of the LS samples had methylation in two or more genes
(35.4%) and thirty three had methylation in one or more samples (56.9%).
When combining SCC and LS tissues five were methylated in three genes (4.4%),
thirty six were methylated in two genes or more (28.6%), and eighty five had methylation
in one or more genes (61.6%). This data is summarized in Figure 3.5 which depicts
methylation analysis of histological type and the number of genes methylated per
specimen.
80.00%

70.00%

Percent of Histological Grouping

60.00%

50.00%

Normal
SCC

40.00%

LS
30.00%

20.00%

10.00%

0.00%
4

> or =3

> or =2

> or =1

Genes Methylated per Specimen

Figure 3.5 Methylation by histological type using all genes.
Finally for normal adjacent samples, one sample exhibited methylation in 3 genes
out of a total thirty samples (3.3%), and fifteen samples were methylated in one and two
genes (50.0%).
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CHAPTER 4
DISCUSSION AND CONCLUSION

4.1

General Discussion
By studying the molecular change in methylation patterns associated with

transitions from normal to lichen sclerosis and finally to squamous cell carcinoma in
human vulva an etiological model of disease was formed. Four genes were chosen that
are commonly inactivated in human neoplasia; p16, p15, and Glutathione S-Transferase
P1 (GSTP1) and O6 -methylguanine-DNA Methyltransferase (MGMT). The two genes
that appear to be most promising for early prognosis of vulval squamous cell carcinoma
are p16 and p15. Overall, the methylation results observed in the present study were not
abnormal from those seen in other studies.
4.2

p16 and p15 Genes
The p16 and p15 genes are both cyclin dependent kinase inhibitors (CDKs) which

regulate cell division. Hypermethylation of CpG islands in the tumor suppressor gene
p16 occurs frequently in various types of human malignancies (Xing, Nie et al. 1999;
Kim, Nelson et al. 2001; Gasco, Sullivan et al. 2002; Kresty, Mallery et al. 2002; Holst,
Nuovo et al. 2003). Inactivation of the p16 gene has been observed in esophageal
squamous cell carcinoma (Xing, Nie et al. 1999), vulvar squamous cell carcinoma
(Gasco, Sullivan et al. 2002), and others. The frequency of p16 mutations in primary
tumors also vary among reports from 0-50%, and differed significantly between different
ethnic groups if not due to experimental variation (Xing, Nie et al. 1999). Coincident
inactivation of p16 in vulvar SCC was found previously at an occurrence of 60% in 36
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cases (Gasco, Sullivan et al. 2002). p15 is highly homologous to p16, particularly in
exon 2, where they share 91% sequence identity (Hannon and Beach 1994), indicating
their origination by a gene duplication event (Xing, Nie et al. 1999). The p15 gene is also
commonly hypermethylated in human neoplasms (Yeh, Chang et al. 2003), however,
hypermethylation in both p16 and p15 is uncommon (Issa 2004).
This study demonstrated p16 and p15 were found to exhibit a high frequency of
promoter methylation in vulvar SCC. As a percentage of SCC tissues analyzed
methylation was found p16 and p15 at 26% and 34%, respectively. Lichen sclerosis (LS)
tissues were also informative yielding 22% methylation in p16 and 31% in p15. These
values for SCC and LS tissues were both found to be statistically different from normal
tissues analyzed. This relationship showing increasing methylation from normal to LS
and SCC suggests that epigenetic silencing of p16 is an early event in vulvar neoplasia.
Both p16 and p15 data present a clear picture with exceptionally low methylation patterns
in normal tissues. These data correlate well with data from others studying SCC and
other cancers. p15 exhibited methylation in the cancer associated normal tissues only.
This could be an indicator that the associated normal tissues for this marker are
undergoing methylation leading to cell cycle disruption early. Another explanation is
that there is a cancer field effect present in neighboring tissues.
4.3

GSTP1 Gene
GSTP1 is a member of the GST superfamily of four genes that provide important

defense against oxidative damage to DNA and other cellular macromolecules (Gilliland,
Harms et al. 2002). GSTP1 is a vital gene that plays an important role in protecting cells
from cytotoxic and carcinogenic agents (Zhong, Tang et al. 2002). Published data has
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demonstrated that GSTP1 methylation correlates highly with many primary tumors
including: prostate carcinoma (83%) breast cancer (31%), renal cancer (20%), lung
cancer (9%), colon cancer (4%), and others (Esteller, Corn et al. 1998). Primary tumors
reported by Esteller, et al. 1998 not exhibiting significant methylation include
endometrial carcinoma, melanoma, head and neck carcinoma, and others. Hepatocellular
Carcinomas exhibited a background level in normal tissues of four out of a total forty
samples (10%) (Zhong, Tang et al. 2002).
GSTP1 was not found to have a statistically significant difference between SCC,
LS, or normal tissues in this study. A high methylation rate was found in normal tissues
adjacent to SCC and LS tissues. Although this was not statistically significant from SCC
and LS it still raised concern. Further, other groups found similar trends of high GSTP1
methylation in normal tissues. Zhong, Tang et al. 2002 found 10% of hepatocellular
carcinomas methylated in normal tissues. Since none of the ten unassociated tissues were
found to be methylated, the methylation in the normal adjacent tissues may be due to the
proximal association with SCC or possibly a cancer field effect (Dong, Ip et al. 2002).
4.4

MGMT Gene
An association between the DNA repair gene MGMT and cancer has been

recognized in brain, colon lymphoma, and non-small cell lung cancer (Esteller, Toyota et
al. 2000). Loss of MGMT is associated with increased risk of carcinogenesis and
increased sensitivity to methylating agents (Gerson 2004).
In this study the DNA repair gene MGMT had very high methylation status in all
three histological cell types, all very near 50%. There was no statistically significant
difference in any of the three histological types. Ranges in methylation of published data
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have been broad, from 2% in bladder cancer (Maruyama, Toyooka et al. 2001) to 60% in
esophageal carcinoma (Eads, Lord et al. 2001). A high level background in normal
tissues has been observed. The studies of esophageal carcinoma at The University of
Southern California, Keck School of Medicine, Norris Comprehensive Cancer Center,
Los Angeles California included normal stomach tissue (NE) samples that exhibited a
high propensity for methylation (Eads, Lord et al. 2001). The Los Angeles group found
thirty one of fifty one normal samples (60%) that displayed methylation. The group
statistically analyzed the data using Fisher’s Exact Test to compare the esophageal
carcinoma tissues to normal stomach tissues and found that there was no significant
difference (no p value reported.) Other groups have found a high incidence of
methylation in normal tissues. The James G. Herman (the architect of MSP) lab group
from John’s Hopkins Comprehensive Cancer Center, Baltimore Maryland found similar
results when studying aberrant methylation in sputum of lung cancer patients. The group
originally studied ten cases of matched SCC and sputum normal tissues. Of these, three
cases of the normal sputum were methylated (Palmisano, Divine et al. 2000).
Among samples that displayed methylation in SCC there were no cases that
displayed methylation in all four genes. Two samples displayed methylation in three
genes (3.3%) and the trend increased to sixty eight percent exhibiting methylation in at
least one gene. LS tissues displayed a somewhat similar trend with one sample
displaying methylation in all four genes and three exhibiting methylation in three genes.
As with SCC the methylation trend increased as the number of genes methylated
decreased. Fifty seven percent of LS samples had at least one gene methylated. Normal
samples exhibiting methylation in three or more genes was found in one sample. Fifteen
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normal samples were methylated in one and two genes increasing the total percentage of
normal methylation to fifty percent. If excluding the MGMT gene this number the
number of normal genes methylated drops dramatically to approximately thirty percent.
The methylation of the panel of genes selected indicates an apparent trend among cases
from SCC to LS to normal tissues.
4.5

Conclusion
In recent years cancer has begun to be understood not only as a genetic disease,

but also as an epigenetic one (Baylin and Herman 2000). It appears that these pathways
are interrelated by a complex network involving many distinct processes. Changes in
DNA methylation along with chromatin modifications are at the heart of epigenetic
changes. DNA methylation patterns are tremendously altered in neoplasia and are often
comprised of genomic level loss of methylation and both gains and losses of regional
methylation. In particular aberrant promoter hypermethylation is associated with
inappropriate gene silencing at every step in tumor progression (Jones and Baylin 2002).
Aberrant DNA methylation of promoter sequences of genes has been associated with
numerous types of human cancers including squamous cell carcinoma. Understanding
the evolution of abnormal methylation patterns could provide an insight into human
cancer development. This insight could lead to early diagnosis and provide us with
possible targets for molecular gene therapy. One such approach is treatment with 5-azacytidine to prevent hypermethylation of tumor suppressor genes. Furthermore, increased
understanding may lead to other pharmaceutical interventions that could be more
effective and less invasive than those currently employed.
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Valuable data was obtained that contributes to the range of information being
collected on: aberrant DNA methylation, gene silencing, and for the progression of vulvar
disease from normal to LS to SCC. Further studies of these genes and their functions
would contribute to these data. Other tumor suppressors and proto-oncogenes should be
studied to increase the overall knowledge of silenced genes associated with vulvar
cancer. Primarily proteins that the four genes encode should be studied. It is known that
post transcriptional events are also important in cell function. The protein expression of
the normal genes and expressed mutant genes could be monitored by the use of
antibodies specific. Protein data would strengthen the results to an even greater degree
and would give unarguable conclusion to the fates of these genes.
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APPENDIX A

PHENOL AND CHLOROFORM EXTRACTION PROCEDURE
Preparation of Genomic DNA from Mammalian Tissue
DNA Isolation
1. Excise an immediately mince tissue quickly and freeze in liquid nitrogen.
2. Grind 200 mg to 1g tissues with prechilled mortar and pestle, or crush with hammer to
fine powder.
3. Add 500 µl grinding buffer to the tissue in a 1.5 ml Eppendorf tube and vortex for several
minutes.
4. Spin the samples in a microfuge for 15 minutes.
5. Decant the solution and add 500 µl of lysis buffer and add 10 µl (6 Units) of proteinase K
to each sample. Digest at 37° for 12 hours.
6. Add 500 µl of phenol to each tube. Vortex briefly and centrifuge for 10 minutes.
7. Making certain not to disturb the interphase, transfer aqueous top solution to a clean
labeled tube and add 500 µl of chloroform. Vortex briefly and centrifuge for 10 minutes.
8. If a white precipitate is present at the aqueous/organic interface, reextract the organic
phase and pool aqueous phases.
9. Carefully remove the top aqueous phase containing the DNA using a 200 ul pipettor and
transfer to a new tube.
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APPENDIX B

ETHANOL PRECIPITATION OF DNA
1. Add 1/10 volume of 3M sodium acetate, pH 5.2, to the solution of DNA. Mix by
vortexing briefly or by flicking the tube several times with your finger.
2. Add 2 to 2.5 volumes of ice cold 100% ethanol. Mix by vortexing and place in crushed
dry ice for 5 minutes or longer. Alternately, the tubes can be placed at -80° for 1 hour or
at -20° overnight.
3. Spin 5 minutes in a microcentrifuge at high speed and remove the supernatant.
4. Add 1 ml of room temperature 70% ethanol. Invert the tube several times and
microcentrifuge as in step 6.
5. Remove the supernatant. Dry the pellet in a desiccator under vacuum or in a hood.
6. Dissolve the dry pellet in an appropriate volume of water or TE buffer (10mM Tris-HCL,
1mM EDTA), pH8.0
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APPENDIX C

BISULFITE TREATMENT OF DNA
This protocol was adapted from Frommer et.al.1992.
1.
2.
3.
4.

Dilute DNA (up to 2 mg) into 50 ml with distilled H2 O.
Add 5.5 ml of 2M NaOH.
Incubate at 37°C for 10 minutes (to create single stranded DNA).
Add 30 ml of 10 mM hydroquinone (Sigma) to each tube, freshly prepared by adding 55
mg of hydroquinone to 50 ml of water.
5. Add 520 ml freshly prepared 3M Sodium bisulfite (Sigma S-8890), prepared by adding
1.88 gm of sodium bisulfite per 5 ml of H2 O, and adjusting pH to 5.0 with NaOH.
6. Assure that reagents are mixed with DNA.
7. Layer with mineral oil.
8. Incubate at 50°C for 16 hours (avoid incubations of much longer duration as methylated
C will start converting to T).
9. Remove oil.
10. Add 1 ml of DNA wizard cleanup (Promega A7280) to each tube and add mixture to
miniprep column in kit.
11. Apply vacuum (manifold makes this convenient).
12. Wash with 2 ml of 80% isopropanol.
13. Place column in clean, labeled 1.5 ml tube.
14. Add 50 ml of heated water (60-70°C).
15. Spin tube/column in microfuge for 1 minute.
16. Add 5.5 ml of 3 M NaOH to each tube, and incubate at room temperature for 5 minutes.
17. Add 1 ml glycogen as carrier (we use Boehringer glycogen, undiluted).
18. Add 33 ml of 10 M NH4 Ac, and 3 volumes of ethanol.
19. Precipitate DNA as normal (overnight at -20°C, spin 30 mins), wash with 70% ethanol,
dry pellet and resuspend in 20 ml water.
20. Treat DNA like RNA (keep cold, minimize freeze/thaws, store at -20°C)
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APPENDIX D

METHYLATION SPECIFIC POLYMERASE CHIAN REACTION
This protocol was adapted from other protocols to allow for consistent results using the
primers for this experiment only. Primers are all unique in that annealing is optimal at different
temperatures. Other factors such as MgCl2 concentration must be optimized for the primers and
type of PCR that is to be utilized.

1. Prepare a master mix (on ice) containing the following for each sample to be analyzed.
Add 10% to each total volume to account for pipetting errors.
2. For MSP use a 25uL reaction containing the following.
a. 2.5 µl 10X taq gold buffer
b. 3.0 µl of 25mM MgCl2
c. 0.125 µl taq gold polymerase
d. 2.5 µl Redi- Load
e. 1.0 µl 10mM total dNTP’s
d. Primers at .5 µM final concentration.
3. Add water filtered in a 0.2 µM filter to achieve final volume of master mix and vortex
briefly.
4. Distribute 24 µl in to each 200 µl tube. Add 50 ng of DNA to each reaction (If 1 µg
DNA was dilute to 40 µl after bisulfite treatement use 2ul.)
5. If not using a thermal cycler with a heated lid cover the samples with mineral oil.
*Notes on nested PCR
If ‘nested’ PCR is to be used, the above steps should be using the outside primers.
Subsequent PCR’s should be set up with 23 µl of the master mix in each tube. 4 µl of
product from the first PCR will be used for each sample. 2 µl will be used with the
methylated primers and 2 µl will be used with the unmethylated primers.
Thermal Cycling Parameters
1. Initial Denaturation. For Amplitaq Gold Polymerase this is performed at 95° for 9
minutes. This is to activate the thermostable properties.
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2. Cycling. Amplification involves 20 to 40 cycles. For the first step in a ‘nested’ PCR
30 cycles are used, followed by the inside PCR at 30 or 35 cycles. a denaturing step at 95
for 1 minute Anealing. Annealing should be at the
temperature that has been found to
be optimal for the primers in use for 1 minute.
Extension. Occurs with most reactions at 72°. This should be a one minute step.
2. Final Extension. Seven minutes at 72°.
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APPENDIX E

AGAROSE GEL ELECTROPHORESIS
1. Prepare a 2 – 3% agarose gel by adding the appropriate amount of agarose to TBE buffer.
The total amount of gel should be determined by the size of the gel apparatus, and the
thickness required for sufficient loading of DNA product.
2. Microwave the gel in a Pyrex flask until boiling. Continue to heat until all agarose
particles are melted.
3. Let the gel cool at room temperature until it is approximately 60°.
4. Add ethidium bromide to a final concentration of 0.5 mg / ml.
5. Pour into the gel casting apparatus and let cool till the gel reaches room temperature.
6. Place the gel and the casting apparatus into the gel unit. Fill with TBE until the gel is
covered by 1mm of TBE.
7. If DNA rediload is used with the PCR reaction then the product can be loaded directly
into the gel. If not add approximately 1 - 2 µl of bromophenol blue loading dye.
8. Cover and run at 5V per centimeter of gel until the loading dye travels 4 – 5 cm.
9. Visualize with UV on a gel viewing apparatus.
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APPENDIX F
p16 BISULFITE TREATED SEQUENCE

Accession Number NM_058197
(Outside Forward Primer) GA AGAAAGAGGA
61 AGGATTTGAG GGATAGGGTC GGAGGGGGTT TTTTCGTTAG TATCGGAGGA AGAAAGAGGA
TCCTAAACTC CCTATCCCAG CCTCCCCCAA AAAAGCAATC ATAGCCTCCT TCTTTCTCCT

TTATTAGA GGGTGGGGCG
GGGGTTGGè
TTATTAGA GGGTGGGGTG
121 GGGGTTGGTT GGTTATTAGA GGGTGGGGCG
CCCCAACCAA CCAATAATCT CCCACCCCGC

GATCGC (Methylated Forward)è
GATTGT (Unmethylated Forward)è
GATCGCGTGC GTTCGGCGGT TGCGGAGAGG
CTAGCGCACG CAAGCCCCCA ACGCCTCTCC

181 GGGAGAGTAG GTAGCGGGCG GCGGGGAGTA GTATGGAGTC GGCGGCGGGGA GTAGTATGG
CCCTCTCATC CATCGCCCGC CGCCCCTCAT CATACCTCAG CCGCCGCCCCT CATCATACC

241 AGTTTTCGGT TGATTGGTTG GTTACGGTCG
TCAAAAGCCA ACTAACCAAC CAATGCCAGC
çAATGCCAGC
çAATACCAAC

CGGTTCGGGG
GCCAAGCCCC
GCCAAGCCCC
ACCAAACCCC

TCGGGTAGAGG AGGTGCGGG
AGCCCATCTCC TCCACGCCC
AG (Methylated Reverse)
AAC (Unmethylated Reverse)

301 CGTTGTTGGA GGCGGGGGCG TTGTTTAACG TATCGAATAG TTACGGTCGGA GGTCGATTT
GCAACAACCT CCGCCCCCGC AACAAATTGC ATAGCTTATC AATGCCAGCCT CCAGCTAAA

361 AGGTGGGTAG AAGGTTTGTA GCGGGAGTAG GGGATGGCGG GCGATTTTGGA GGACGAAGT
TCCACCCATC TTCCAAACAT CGCCCTCATC CCCTACCGCC CGCTAAAACCT CCTGCTTCA
çCCACCCATC TCCCAAACAT C (Outside Reverse Primer)
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APPENDIX G

p15 BISULFITE TREATED SEQUENCE

Accession Number S75756
TT
T
61 TTTTTGGTTT
AAAAACCAAA

AGTTGAAAAC
AGTTGAAAAT
AGTTGAAAAC
TCAACTTTTG

GGAATTTTTT
GGAATTTTTT
GGAATTTTTT
CCTTAAAAAA

GTC (Methylated Forward)è
GTTG (Unmethylated Forward)è
GTCGGTTGGT TTTTTATTTT GTTAGAGCGA
CAGCCAACCA AAAAATAAAA CAATCTCGCT

121 GGCGGGGTAG TGAGGATTTC GCGACGCGTT CGTATTTTGC GGTTAGAGCG GTTTTGAGTT
CCGCCCCATC ACTCCTAAAG CGCTGCGCAA GCATAAAACG CCAATCTCGC CAAAACTCAA

181 CGGTTGCGTT CGCGTTAGGC GTTTTTTTTT AGAAGTAATT TAGGCGCGTT CGTTGGTTTT
GCCAACGCAA GCGCAATCCG CAAAAAAAAA TCTTCATTAA ATCCGCGCAA GCAACCAAAA

241 TGAGCGTTAG
ACTCGCAATC
çGCAATC
çTCACAATC

GAAAAGTTCG
CTTTTCAAGC
CTTTTCAAGC
CTTTTCAAAC

GAGTTAACGA TCGGTCGTTC GGTTATTGTA CGGGGTTTTA
CTCAATTGCT AGCCAGCAAG CCAATAACAT GCCCCAAAAT
CTCAATTG (Methylated Reverse)
CTCAATTA (Unmethylated Reverse)
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APPENDIX H

GSTP1 BISULFITE TREATED SEQUENCE
Accession Number AY324387
(Outside Forward Primer) GGATTTT AGGGCGTTTT TTTè
G
1681 AGGTTTTTTC GGTTAGTTGC GCGGCGATTT CGGGGATTTT AGGGCGTTTT TTTGCGGTCG
TCCAAAAAAG CCAATCAACG CGCCGCTAAA GCCCCTAAAA TCCCGCAAAA AAACGCCAGC

TTCGGGG
ATGTTTGGGG
1741 ACGTTCGGGG
TGCAAGCCCC

TGTAGCGGTC GTC (Methylated Forward)è
TGTAGTG (Unmethylated Forward)è
TGTAGCGGTC GTCGGGGTTG GGGTCGGCGG GAGTTCGCGG GATTTTTTAG
ACATCGCCAG CAGCCCCAAC CCCAGCCGCC CTCAAGCGCC CTAAAAAATC

1801 AAGAGCGGTC GGCGTCGTGA TTTAGTATTG
TTCTCGCCAG CCGCAGCACT AAATCATAAC
çGCAGCACT AAATCATAAC
çACAACACT AAATCATAAC

GGGCGGAGCG GGGCGGGATT ATTTTTATAA
CCCGCCTCGC CCCGCCCTAA TAAAAATATT
CCCG (Methylated Reverse)
CCCACC (Unmethylated Reverse)
çCCCTAA TAAAAATATT

1861 GGTTCGGAGG TCGCGAGGTT TTCGTTGGAG TTTCGTCGTC GTAGTTTTCG TTATTAGTGA
CCAAGCCTCC AGCGCTCCAA AAGCAACCTC AAAGCAGCAG CATCAAAAGC AATAATCACT
CCAAGCC (Outside Reverse Primer)

1921 GTACGCGCGG TTCGCGTTTT CGGGGATGGG GTTTAGAGTT TTTAGTATGG GGTTAATTCG
CATGCGCGCC AAGCGCAAAA GCCCCTACCC CAAATCTCAA AAATCATACC CCAATTAAGC
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Kirk Robert Hutchinson was born in Baton Rouge, Louisiana, on June 26, 1978. His
loving parents were living in Baton Rouge at the time, where his mother was student teaching
and his father was in the last year of his Ph.D. Perhaps his longing to be an eternal student was
inherited.
Upon completion of his final degree, Kirk’s father moved this small family to
Winnsboro, Louisiana, where Kirk would enjoy growing up in a town with less than six thousand
residents. Living in a quiet town, Kirk was able to enjoy many outdoor activities such as fishing
with his parents. Kirk attended Winnsboro public schools until the beginning of his senior year.
It was this year that his father would have the opportunity to advance with his position through
Louisiana State University. The still rather small, but close family moved to Saint Joseph,
Louisiana, on the bank of the Mississippi River in Tensas Parish. It was in Saint Joseph that
despite a rough year (one in which Kirk would barely skate through trigonometry), Kirk would
graduate from Tensas Academy. Perhaps it was the move in general, or the fact that there could
be a city that was one-sixth the size of Winnsboro that was so shocking. In fact it was said that
when Kirk joined the class at Tensas Academy he was the sixteenth student, therefore
completing the “Sweet Sixteen.” Yes this does refer to a graduating class of sixteen.
It would seem like Kirk did not have a choice in deciding his academic career, for he did
enroll in Louisiana State University in Baton Rouge. Kirk began his academic career in
environmental management systems, but would change his mind and his major at whim. His
first four years were very enjoyable, filled with late nights and partying. In fact Kirk partied
with a focus and tenacity, which was never quite evident in his studies. It was the hand of God
that pushed Kirk through his Bachelor of Science allowing him to graduate in December 2000.
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Kirk, still unsure of his future dreams enrolled again at Louisiana State University as a
non- matriculating student. It was at the end of this semester that Kirk obtained a Research
Associate position in The Department of Agronomy. After a few months in this position he
decided that soils were definitely not of interest to him. He then applied to The Department of
Environmental Studies. The decision was probably based more on the fact that he would have
two environmental titles in future degrees more than anything (two is better than one.) Floating
through the department Kirk stumbled upon Dr. Vincent Wilson. After a brief visit he chose Dr.
Wilson as his major professor. The choice, although Kirk did not know it at the time, was a wise
one. Kirk began to enjoy the molecular research that Dr. Wilson had exposed him to in the
laboratory. In fact he enjoyed molecular methods enough to change positions from The
Agronomy Department to The Department of Biological Sciences. Kirk will be graduating at the
end of the summer semester 2004, still lacking good study habits, but learning them slowly.
He was joined with his gorgeous wife Karlye in December of 2003. Their future remains
unknown. Karlye is considering graduate school at the moment and Kirk, with his genetic
predisposition to graduate school, is also unable to break away from the academic world. Kirk
will be applying to graduate schools to focus further on the cancer research that was introduced
to him by Dr. Wilson.
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